gatifloxacin has been researched along with reserpine in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Floyd, JL; Floyd, JT; Kumar, SH; Smith, KP; Varela, MF | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Drudy, D; Fanning, S; Kyne, L; O'Gaora, P; O'Mahony, R; Quinn, T | 1 |
4 other study(ies) available for gatifloxacin and reserpine
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus.
Topics: Amino Acid Sequence; Bacterial Proteins; Chloramphenicol; Drug Resistance, Multiple, Bacterial; Ethidium; Membrane Transport Proteins; Microbial Sensitivity Tests; Molecular Sequence Data; Onium Compounds; Organophosphorus Compounds; Phylogeny; Sequence Homology, Amino Acid; Sodium Dodecyl Sulfate; Staphylococcus aureus; Trimethoprim; Vancomycin | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Aza Compounds; Bacterial Proteins; Bacterial Toxins; Clostridioides difficile; Dipeptides; DNA Gyrase; DNA, Bacterial; Drug Resistance, Bacterial; Enterotoxins; Enzyme Inhibitors; Fluoroquinolones; Gatifloxacin; Microbial Sensitivity Tests; Molecular Sequence Data; Moxifloxacin; Mutation; Polymerase Chain Reaction; Quinolines; Reserpine; Ribotyping; Sequence Analysis, DNA; Verapamil | 2006 |